SCHEMBL24424915

SCHEMBL24424915

FC(F)(F)C1=CCC(N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 1/20 0.41
GRIN2B Q13224 3/20 0.41
DRD2 P14416 3/20 0.40
DRD3 P35462 2/20 0.40
YTHDC1 Q96MU7 1/20 0.39
DRD4 P21917 1/20 0.38
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
G6PC1 P35575 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
BACE1 P56817 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HTR1D P28221 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150098 0.74 DRD3 (0.60) SLC6A2SLC6A4SLC6A3GRIN2BDRD2
SCHEMBL3376962 0.73 YTHDC1 (0.58) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1
SCHEMBL24424078 0.72 YTHDC1 (0.48) SLC6A2SLC6A4SLC6A3GRIN2BDRD2
SCHEMBL13017781 0.72 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1
SCHEMBL385070 0.71 YTHDC1 (0.54) SLC6A2SLC6A4SLC6A3GRIN2BDRD2
SCHEMBL10320551 0.71 YTHDC1 (0.54) SLC6A2SLC6A4SLC6A3GRIN2BDRD2
SCHEMBL21048038 0.71 YTHDC1 (0.44) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1
SCHEMBL21048039 0.71 YTHDC1 (0.44) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1
SCHEMBL3373138 0.70 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1
SCHEMBL2563108 0.70 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3GRIN2BYTHDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD SLC6A2 4229/4885SLC6A4 3016/4885SLC6A3 4114/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD SLC6A2 2968/4885SLC6A4 1855/4885SLC6A3 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.